Faculty, Staff and Student Publications
Publication Date
1-1-2022
Journal
Advances in Radiation Oncology
DOI
10.1016/j.adro.2022.100989
PMID
36420184
PMCID
PMC9677209
PubMedCentral® Posted Date
May 2022
PubMedCentral® Full Text Version
Post-print
Abstract
PURPOSE: An evolutionary action scoring algorithm (EAp53) based on phylogenetic sequence variations stratifies patients with head and neck squamous cell carcinoma (HNSCC) bearing
METHODS AND MATERIALS: Eighty-one resection samples from patients treated surgically for stage III or IV human papillomavirus-negative HNSCC with high-risk pathologic features, who received either radiation therapy + cetuximab + cisplatin (cisplatin) or radiation therapy + cetuximab + docetaxel (docetaxel) as adjuvant treatment in a phase 2 study were subjected to
RESULTS: At a median follow-up of 9.8 years, there was a significant interaction between EAp53 group and treatment for overall survival (
CONCLUSIONS: The docetaxel arm was associated with better survival than the cisplatin arm for patients with wild-type or low-risk EAp53. These benefits appear to be largely driven by a reduction in DM.
Published Open-Access
yes
Recommended Citation
Michikawa, Chieko; Torres-Saavedra, Pedro A; Silver, Natalie L; et al., "Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234" (2022). Faculty, Staff and Student Publications. 1728.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/1728
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Oncology Commons